Clinical trials: Ovarian Epithelial Cancer Recurrent
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
This is a phase 1b/2 open-label, multicenter, basket study to determine the safety, anti-tumor activity, tolerability, and pharmacokinetics /pharmacodynamics of AsiDNA in combination with olaparib in participants with recurrent…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
- Trial name
- NCT05700669
- Testing
- AsiDNA, Olaparib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Valerio Therapeutics
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and best dose of ganetespib when given together with paclitaxel and to see how well they work in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal…
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT01962948
- Testing
- paclitaxel, ganetespib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fox Chase Cancer Center
Recurrent Epithelial Ovarian Cancer
Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer
Rationale Ovarian cancer is the 3rd most common gynecologic malignancy in Korea. The standard treatment is tumor debulking surgery with or without adjuvant chemotherapy.
- Trial name
- SABR-ROC (NCT05444270)
- Testing
- Standard salvage therapy, Standard salvage therapy + SABR
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Yonsei University
Ovarian Epithelial Cancer Recurrent, Platinum-resistant
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor
Patients with first recurrent resistance ovarian cancer and disease progression with peritoneal carcinomatosis will undergo PIPAC procedure.
- Trial name
- PARROT (NCT02735928)
- Testing
- Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Catholic University of the Sacred Heart
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer…
- Trial name
- NCT03330405
- Testing
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2
- Where
- 66 sites in United States, Australia and 7 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
This is a Phase II study. The purpose of this study is to find out what effects, good and/or bad enzalutamide has on the patient and the cancer. All patients who enter the study will be closely monitored for side-effects.
- Conditions
- Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma
- Trial name
- NCT01974765
- Testing
- Enzalutamide
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Platinum Resistant Ovarian Cancer
A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.
- Trial name
- OVAL (NCT03398655)
- Testing
- VB-111 + Paclitaxel
- Where
- 94 sites in United States, Israel and 3 more
- Volunteers
- 408 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Male Breast Cancer, Recurrent Melanoma
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
This pilot trial studies propranolol hydrochloride in treating patients with locally recurrent or metastatic solid tumors that cannot be removed by surgery.
- Conditions
- Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, Stage IV Melanoma
- Trial name
- NCT02013492
- Testing
- propranolol hydrochloride, Correlative Studies
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- William Carson
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
This phase I trial is studying the side effects and best dose of decitabine when given together with pegylated liposomal doxorubicin hydrochloride and vaccine therapy in treating patients with recurrent ovarian epithelial cancer…
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT01673217
- Testing
- decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
- Trial name
- TIVO (NCT01853644)
- Testing
- Tivozanib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to…
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
- Trial name
- NCT02785250
- Testing
- DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
- Where
- 9 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Ovarian Epithelial Cancer Recurrent, Fallopian Tube Carcinoma
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian cancer.
- Conditions
- Ovarian Epithelial Cancer Recurrent, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01611766
- Testing
- Secondary Cytoreductive Surgery, Salvage Chemotherapy
- Where
- 4 sites in China
- Volunteers
- 356 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Recurrent Ovarian Cancer
Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
A first in human experimental treatment in which an experimental medicine,Nuc-1031, is used in combination with a standard cancer medicine, carboplatin, to treat ovarian cancer which reappear after standard cancer treatment.
- Trial name
- ProGem2 (NCT02303912)
- Testing
- Nuc-1031 and Carboplatin
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Imperial College Healthcare NHS Trust
Recurrent Epithelial Ovarian Cancer
Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
In this study the investigators will include patients with relapsed epithelial ovarian cancer. In spite of increased rates of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and…
- Trial name
- NCT01334047
- Testing
- DC-006 vaccine
- Where
- Norway
- Volunteers
- 5 people
- Sponsor
- Steinar Aamdal
Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent).
- Conditions
- Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT00551070
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib
- Where
- 49 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Epithelial Cancer Recurrent, Fallopian Tube Cancer
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced ovarian, fallopian tube or primary peritoneal cancer.
- Conditions
- Ovarian Epithelial Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01899599
- Testing
- PankoMab-GEX
- Where
- 50 sites in Germany, Hungary and 6 more
- Volunteers
- 216 people
- Sponsor
- Glycotope GmbH
HIV Infection, Recurrent Anal Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
This phase I clinical trial is studying the side effects and the best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with metastatic or recurrent solid tumors and human…
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer
- Trial name
- NCT01249443
- Testing
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase I trial studies the side effects and best dose and schedule of sirolimus when given together with vaccine therapy in treating patients with stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity…
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube Cancer
- Trial name
- NCT01536054
- Testing
- ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Epithelial Cancer Recurrent
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.
- Trial name
- RETRO-ROC (NCT02394015)
- Testing
- Trabectedin and Pegylated Liposomal Doxorubicin
- Volunteers
- 90 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario